KeyBanc raised the firm’s price target on ICU Medical (ICUI) to $175 from $173 on higher estimates, while keeping an Overweight rating on the shares. The firm remains encouraged by ICU’s underlying operational progress as well as ability to raise 2025 EPS/EBITDA guidance, despite continued macro headwinds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICUI: